Dementia Drugs Market Expected to Reach $19.7 Billion by 2031 ; CAGR of 8.5% from 2022 to 2031

Allied Market Research published a report, titled, "Dementia Drugs Market by Indication (Lewy Body Dementia, Parkinsons Disease Dementia, Alzheimers Disease, Vascular Dementia, Other Indications), by Drug Class (Cholinesterase Inhibitors, NMDA Antagonists and its Combination Drugs), by Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2021-2031". According to the report, the global dementia drugs industry generated $8.7 billion in 2021, and is anticipated to generate $19.7 billion by 2031, witnessing a CAGR of 8.5% from 2022 to 2031.

𝑹𝒆𝒒𝒖𝒆𝒔𝒕 𝑺𝒂𝒎𝒑𝒍𝒆 𝑪𝒐𝒑𝒚 𝒐𝒇 𝑹𝒆𝒑𝒐𝒓𝒕-- https://www.alliedmarketresearch.com/request-sample/12379

𝐏𝐫𝐢𝐦𝐞 𝐝𝐞𝐭𝐞𝐫𝐦𝐢𝐧𝐚𝐧𝐭𝐬 𝐨𝐟 𝐠𝐫𝐨𝐰𝐭𝐡
Increase in the prevalence of Alzheimer's disease, advancement in R&D activities for drug development, rise in the adoption of early diagnosis, the growing geriatric population, increase in investment in R&D by players, presence of robust pipeline candidates, increase in public awareness about the disease prevention in developing regions, and the surge in demand for personalized medicines drive the growth of the global dementia drugs market. However, strict government regulations related to product approval and high cost linked to R&D activity restrain the growth of dementia drugs industry. Conversely, accelerated technological advancement in drug discovery techniques and high investment for drug development by the government are expected to offer lucrative opportunity for the dementia drugs market in future.

𝐂𝐨𝐯𝐢𝐝-19 𝐒𝐜𝐞𝐧𝐚𝐫𝐢𝐨
The outbreak of the Covid-19 pandemic had a positive impact on the global dementia drugs market, as it was reported that the pandemic caused a significant rise in the number of dementia patients.
Some research has shown that the COVID-19 infection can increase a person's likelihood of developing dementia and cause the symptoms to show up earlier.
Moreover, COVID-19 shows adverse impact on brain function by reducing the level of consciousness. Thus, increase in COVID-19 infection in patients with Alzheimer's disease increased the demand for dementia drugs during the pandemic.

𝐓𝐡𝐞 𝐀𝐥𝐳𝐡𝐞𝐢𝐦𝐞𝐫'𝐬 𝐝𝐢𝐬𝐞𝐚𝐬𝐞 𝐬𝐞𝐠𝐦𝐞𝐧𝐭 𝐭𝐨 𝐦𝐚𝐢𝐧𝐭𝐚𝐢𝐧 𝐢𝐭𝐬 𝐥𝐞𝐚𝐝𝐞𝐫𝐬𝐡𝐢𝐩 𝐬𝐭𝐚𝐭𝐮𝐬 𝐭𝐡𝐫𝐨𝐮𝐠𝐡𝐨𝐮𝐭 𝐭𝐡𝐞 𝐟𝐨𝐫𝐞𝐜𝐚𝐬𝐭 𝐩𝐞𝐫𝐢𝐨𝐝
Based on indication, the Alzheimer's disease segment held the highest market share in 2021, accounting for around three-fifths of the global dementia drugs market, and is estimated to maintain its leadership status throughout the forecast period. This is owing to the increase in life expectancy, rise in ageing population, and changes in lifestyle. However, the vascular dementia segment is projected to manifest the highest CAGR of 10.0% from 2022 to 2031, owing to an increasing number of people, especially geriatrics and smokers, with high risk of developing vascular dementia as well as increasing understanding of diagnosis modalities.

𝐓𝐡𝐞 𝐜𝐡𝐨𝐥𝐢𝐧𝐞𝐬𝐭𝐞𝐫𝐚𝐬𝐞 𝐢𝐧𝐡𝐢𝐛𝐢𝐭𝐨𝐫𝐬 𝐬𝐞𝐠𝐦𝐞𝐧𝐭 𝐭𝐨 𝐦𝐚𝐢𝐧𝐭𝐚𝐢𝐧 𝐢𝐭𝐬 𝐥𝐞𝐚𝐝𝐞𝐫𝐬𝐡𝐢𝐩 𝐬𝐭𝐚𝐭𝐮𝐬 𝐭𝐡𝐫𝐨𝐮𝐠𝐡𝐨𝐮𝐭 𝐭𝐡𝐞 𝐟𝐨𝐫𝐞𝐜𝐚𝐬𝐭 𝐩𝐞𝐫𝐢𝐨𝐝
Based on drug class, the cholinesterase inhibitors segment held the highest market share in 2021, accounting for nearly two-thirds of the global dementia drugs market, and is estimated to maintain its leadership status throughout the forecast period, owing to increase in the geriatric population, rise in the prevalence of dementia, and growth in drug discovery. However, the NMDA antagonists and its combination drugs segment is projected to manifest the highest CAGR of 9.2% from 2022 to 2031, owing to a rise in the prevalence of neurological disorders, robust R&D by key players toward the disease treatment, and increased hospitalization rate.

𝐅𝐨𝐫 𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐈𝐧𝐪𝐮𝐢𝐫𝐲- https://www.alliedmarketresearch.com/purchase-enquiry/12379

𝐓𝐡𝐞 𝐡𝐨𝐬𝐩𝐢𝐭𝐚𝐥 𝐩𝐡𝐚𝐫𝐦𝐚𝐜𝐢𝐞𝐬 𝐬𝐞𝐠𝐦𝐞𝐧𝐭 𝐭𝐨 𝐦𝐚𝐢𝐧𝐭𝐚𝐢𝐧 𝐢𝐭𝐬 𝐥𝐞𝐚𝐝 𝐩𝐨𝐬𝐢𝐭𝐢𝐨𝐧 𝐝𝐮𝐫𝐢𝐧𝐠 𝐭𝐡𝐞 𝐟𝐨𝐫𝐞𝐜𝐚𝐬𝐭 𝐩𝐞𝐫𝐢𝐨𝐝
Based on distribution channel, the hospital pharmacies segment accounted for the largest share in 2021, contributing to nearly half of the global dementia drugs market, and is projected to maintain its lead position during the forecast period. This is owing to the increase in geriatric population and Alzheimer's patients. However, the online pharmacies segment is expected to portray the largest CAGR of 11.1% from 2022 to 2031, owing to the convenience and cheaper costs of purchasing prescription drugs electronically, especially under the lockdown situation during the COVID-19 pandemic.

𝐍𝐨𝐫𝐭𝐡 𝐀𝐦𝐞𝐫𝐢𝐜𝐚 𝐭𝐨 𝐦𝐚𝐢𝐧𝐭𝐚𝐢𝐧 𝐢𝐭𝐬 𝐝𝐨𝐦𝐢𝐧𝐚𝐧𝐜𝐞 𝐛𝐲 2031
Based on region, North America held the highest market share in terms of revenue in 2021, accounting for more than two-fifths of the global dementia drugs market, and is likely to dominate the market during the forecast period, owing to the increase in R&D investments by numerous companies in the region. However, the Asia-Pacific region is expected to witness the fastest CAGR of 10.6% from 2022 to 2031. Increase in spending capabilities, owing to the evolving healthcare regulatory landscape, increase in the number of patients with chronic diseases, and the government's emphasis on enhancing R&D capabilities for innovative drug development in the region.

𝐋𝐞𝐚𝐝𝐢𝐧𝐠 𝐌𝐚𝐫𝐤𝐞𝐭 𝐏𝐥𝐚𝐲𝐞𝐫𝐬: -
Apotex inc.
Aurobindo Pharma Ltd.
Biogen Idec
Eisai
Eli Lilly and Company
Johnson & Johnson
Abbvie Inc.
F. Hoffmann-La Roche AG
Teva Pharmaceutical Industries
Novartis AG

𝑲𝒏𝒐𝒘 𝑴𝒐𝒓𝒆- https://www.alliedmarketresearch.com/dementia-drugs-market-A12014

𝐎𝐭𝐡𝐞𝐫 𝐓𝐫𝐞𝐧𝐝𝐢𝐧𝐠 𝐑𝐞𝐩𝐨𝐫𝐭𝐬: 𝐢𝐧 𝐋𝐢𝐟𝐞 𝐒𝐜𝐢𝐞𝐧𝐜𝐞 𝑫𝒐𝒎𝒂𝒊𝒏-
𝐒𝐩𝐞𝐜𝐢𝐚𝐥𝐭𝐲 𝐌𝐞𝐝𝐢𝐜𝐚𝐥 𝐂𝐡𝐚𝐢𝐫𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 https://www.alliedmarketresearch.com/specialty-medical-chairs-market-A11457

𝐕𝐢𝐝𝐞𝐨 𝐋𝐚𝐫𝐲𝐧𝐠𝐨𝐬𝐜𝐨𝐩𝐞 𝐌𝐚𝐫𝐤𝐞𝐭 https://www.alliedmarketresearch.com/video-laryngoscope-market-A17524

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
Web: https://www.alliedmarketresearch.com

Alied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

This release was published on openPR.